Bimekizumab
Monoclonal antibody
From Wikipedia, the free encyclopedia
Bimekizumab, sold under the brand name Bimzelx (/bɪmˈzɛlɪks/ bim-ZEL-iks), is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody[6][7] that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and hidradenitis suppurativa.[6]
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Humanized |
| Target | IL17A, IL17F, IL17AF |
| Clinical data | |
| Trade names | Bimzelx |
| Other names | UCB4940, bimekizumab-bkzx |
| License data |
|
| Pregnancy category | |
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6552H10132N1750O2029S42 |
| Molar mass | 147229.87 g·mol−1 |
The most common side effects include upper respiratory tract infections (nose and throat infection) and oral candidiasis (thrush, a fungal infection in the mouth or throat).[6] Injection site reactions were also common, reported in 3% of subjects.[8]
Bimekizumab was approved for medical use in the European Union in August 2021[6][9][10] and in the US in October 2023.[11][12] In November 2024, bimekizumab was approved by the US Food and Drug Administration for the treatment of active moderate-to-severe hidradenitis suppurativa in adults.[13]
Medical uses
Society and culture
Names
Bimekizumab is the international nonproprietary name (INN).[14]
Research
Phase III trials have demonstrated that bimekizumab is superior to not only adalimumab[15] but also secukinumab[16] and ustekinumab[17] for the treatment of plaque psoriasis.
The approval for the treatment of active moderate-to-severe hidradenitis suppurativa (HS) in adults was supported by data from two Phase 3 studies, BE HEARD I and BE HEARD II, which evaluated the efficacy and safety of bimekizumab in the treatment of adults with moderate-to-severe HS.[18][19][20]
